Within a year of the John Innes Centre moving to Norwich in 1967, we were joined by Sir David Hopwood, beginning over 50 years of research into the bacteria Streptomyces.

Half a decade on, we welcome the latest group to join an ongoing quest to understand something so crucial to human health and medicine, led by Professor Matt Hutchings.

We caught up with Matt to understand who he is, what his group will be working on and how he became a leading microbial scientist.

Until I was about 15 I wasnt really interested in anything other than sport and drumming. Then, my aunt gave me a book called DNA for Beginners and I read about the discovery of the structure of DNA and the molecular machines involved in transcription and translation of DNA. Ive been hooked ever since.

Ive been interested in microbiology since I did my PhD and increasingly I want to understand how microbes live and survive in natural environments and how they interact with each other and with plants and animals rather than simply studying them on their own on agar plates.

I studyStreptomycesbacteria because they are so important to humans despite more than 50 years of ground-breakingStreptomycesresearch at the John Innes Centre, we are only just developing the tools we need to study these bacteria in the wild.

My work is focussed in understanding the roles ofStreptomycesand their specialised metabolites, which are small molecules that most likely mediate interactions with other microbes, animals and plants in their natural soil environment. However, we still do not fully understand their functions in nature.

Streptomycesbacteria make lots of specialised metabolites that are widely used in human medicine as antibiotics, immunosuppressants, antiparasitic and anticancer drugs.

The genomes ofStreptomycesbacteria, and many other microbes, contain the instructions for making many more specialised metabolites than they actually make when we grow them in the lab. This is presumably because they are required for competition and survival in their natural environment but not when growing in nice, rich, warm culture media.

I want to understand what they are used for in nature, how these bacteria interact with other organisms and to identify the environmental signals that activate production of all their specialised metabolites.

The results from this work would enable us and others to discover many new molecules that could be useful in medicine and also to use these bacteria as plant probiotics so we can reduce the use of agrochemicals that are harmful to the environment.

The John Innes Centre is the home ofStreptomycesresearch and has many brilliant plant scientists, microbiologists and chemists as well as world-leading research facilities. This makes it the ideal place to do research, particularly since I want to study the interactions betweenStreptomycesbacteria and plants.

I feel fortunate and humbled to be following in the footsteps of Sir David Hopwood, Keith Chater, Mervyn Bibb and Mark Buttner and to work with some many brilliant colleagues. I hope that together we can gain new insights into the ecology of these amazing bacteria.

See the original post here:

Joining the home of Streptomyces research; Introducing Professor Matt Hutchings - The John Innes Centre

Scientists created an online cell atlas containing information on the gene activity of more than 300,000 lung cells taken from patients with idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

The new atlas adds to the knowledge of the complex cellular and molecular mechanisms involved in both diseases, and may assist in the development of new therapies, investigators noted.

Analyses leading up to the creation of the cell atlas were reported in the study, Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis, published in the journal Science Advances.

Although studies in animal models of lung disorders have led to important advances in the understanding of pulmonary fibrosis and COPD, the knowledge of the molecular and cellular mechanisms underlying these diseases is still limited.

In an effort to expand this knowledge, researchers at Yale School of Medicine and their colleagues set out to create a cell atlas containing the genetic profile of a large number of lung cells taken from patients with either IPF or COPD.

As a first step, researchers isolated individual cells from different parts of the lungs, and then used a technique called single-cell RNA sequencing (scRNA-seq) to examine all RNA molecules, or transcripts, produced from active genes on each individual cell.

Through this process, the team analyzed 312,928 cells taken from 32 patients with IPF and 18 with COPD, creating the largest single-cell gene expression (activity) dataset in patients with chronic lung disorders to date. As controls, cells from 28 donor lungs also were analyzed.

This is a technological accomplishment and is a new perspective on the two diseases, but it is also the starting point for analysis that will lead to a better understanding of the disease and the development of therapy, Ivan Rosas, MD, said in a news story. Rosas is chief of pulmonary, critical care and sleep medicine in the Department of Medicine at Baylor College of Medicine, and co-senior author of the study.

When investigators compared the different populations of cells isolated from patients, they found that cells lining the surface of the lungs (epithelial cells) in IPF patients were very different from those found in COPD patients. The team also discovered a new population of abnormal epithelial cells in the lungs of IPF patients that never had been described before.

Additionally, they found IPF patients had an excessive number of a sub-type of cells forming the lining of blood vessels in the lungs, called vascular endothelial cells.

When we analyzed the data we were surprised by how dramatically different were cells obtained from patients with PF from all other lungs we actually found cells that were not described before, and this may have significant implications on diagnosis and management for the disease, saidNaftali Kaminski, MD, chief of pulmonary, critical care and sleep medicine at Yale, and co-senior author of the study.

The identification and detailed description of aberrant cell populations in the IPF lung may lead to identification of novel, cell type-specific therapies and biomarkers. Last, our IPF cell atlas provides an interactive and highly accessible resource to allow the exploration of cell specific changes in gene expression in lung health and disease and thus accelerate discovery and translation, the researchers wrote.

Rosas began the study while at Harvard Medical School, and now will continue it at Baylor.

Chronic lung diseases are one of the leading causes of morbidity and death in diagnosed patients, but this innovative technology is the starting point for more pointed research in terms of the pathogenesis and the mechanisms of the disease and also the potential therapy that could be derived from the information, Rosas said.

The cell atlas is available to the public, allowing other researchers to conduct their own independent research based on these data.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells cells that made up the lining of blood vessels found in the umbilical cord of newborns.

Total Posts: 110

Patrcia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

Link:

Scientists Create Cell Atlas of Gene Activity Information of IPF and COPD Patients - Pulmonary Fibrosis News

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Accelrys Inc., ID Business Solutions, Ltd., Affymetrix Inc., CLC bio A/S, Agilent Technologies Inc., GenoLogics Life Sciences Software, Inc., Life Technologies Corporation, and Illumina Inc. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Global Bioinformatics Market is expected to be around US$ 17 Billion by 2025 at a CAGR of 14% in the given forecast period.

Browse Full Report: https://www.marketresearchengine.com/bioinformatics-market-report

The Global Bioinformatics Market is segmented on the lines of its sector, product and service application and regional. Based on sector segmentation it covers medical biotechnology, animal biotechnology, academics, agricultural biotechnology, forensic biotechnology, environmental biotechnology and other sectors. Under product and service segmentation it covers knowledge management tools, bioinformatics services and bioinformatics platforms. Based on application segmentation it covers genomics, proteomics, chemoinformatics and drug design, transcriptomics, molecular phylogenetics, metabolomics and other applications. The Global Bioinformatics Marketis geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Bioinformatics marketis the mixture of both biology and information technology. It is generally used in organizing the biological data in the sector of medical research and development of medicines and drugs. Bioinformatics relates with storage, annotation, recording, analysis and retrieval of nucleic acid sequence, structural information and protein sequence. It is used in different sectors and applications in medicine and biology including molecule studies, protective drugs, chromosome therapy, drug innovations, biotechnology and forensic analysis of microorganisms. The boom of the bioinformatics is being augmented by means of the growing function of IT in the healthcare zone in conjunction with robust technical advancements. The employment of IT has enabled easy processing, storage, retrieval, access of data.

The Global Bioinformatics Market has been segmented as below:

The Global Bioinformatics Market this market is segmented on the basis of Sector Analysis, Product and Service Analysis, Application Analysis and Regional Analysis.

By Sector Analysis this market is segmented on the basis of Medical Biotechnology, Animal Biotechnology, Academics, Agricultural Biotechnology, Forensic Biotechnology, Environmental Biotechnology and Other Sectors.By Product and Service Analysis this market is segmented on the basis of Knowledge Management Tools, Bioinformatics Services and Bioinformatics Platforms.By Application Analysis this market is segmented on the basis of Genomics, Proteomics, Chemoinformatics and Drug Design, Transcriptomics, Molecular Phylogenetics, Metabolomics and Other Applications.By Regional Analysis this market is segmented on the basis of North America, Europe, Asia-Pacific and Rest of the World.

The scope of the report includes a detailed study of global and regional markets for Global Bioinformatics Market with the reasons given for variations in the growth of the industry in certain regions.

The major driving factors of Global Bioinformatics Market are as follows:

The restrainingfactors of Global Bioinformatics Market are as follows:

This report provides:

1) An overview of the global market for Bioinformatics and related technologies.

2) Analyses of global market trends, with data from 2015, estimates for 2016 and 2017, and projections of compound annual growth rates (CAGRs) through 2024.

3) Identifications of new market opportunities and targeted promotional plans for Global Bioinformatics Market.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

Request Sample Report: https://www.marketresearchengine.com/bioinformatics-market-report

Table of Contents

1 INTRODUCTION

2 Research Methodology

2.1 Research Data2.2 Market Size Estimation2.3 Market Breakdown and Data Triangulation2.3.1 Key Data From Secondary Sources2.3.2 Key Data From Primary Sources2.3.2.1 Key Industry Insights2.3.3 Assumptions for the Study2.4 Macroeconomic Factor Analysis2.4.1 Introduction2.4.2 Demand-Side Analysis2.4.2.1 Healthcare Expenditure Pattern2.4.3 Supply-Side Analysis2.4.3.1 Number of New Product Launches

3 Executive Summary

4 Premium Insights

5 Market Overview

6 Bioinformatics Market, By Sector

7 Bioinformatics Market, By Products & Services

8 Bioinformatics Market, By Application

9 Bioinformatics Market, By Region

10 Competitive Landscape

11 Company Profiles

11.1 Introduction

11.2 Illumina, Inc.

11.3 Thermo Fisher Scientific Inc.

11.4 Qiagen N.V.

11.5 Agilent Technologies

11.6 Applied Biological Materials (ABM)

11.7 Biomax Informatics Ag

11.8 DNAnexus, Inc.

11.9 ID Business Solutions Ltd.

11.10 Perkinelmer, Inc.

11.11 Waters Corporation

Other Related Market Research Reports:

Biofertilizer Market Key Manufactures and Opportunity Analysis By 2022

Bioburden Testing Market is Expected to Grow US$ 907 Million By 2022

Bio Solids Market Key Manufactures and Opportunity Analysis By 2022

Media Contact

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com

See original here:

Bioinformatics Market 2020: Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast- 2025 - Cole of Duty

Rosalind Franklin at age 25. Elliott & Fry/ National Portrait Gallery, London, CC BY-NC-ND

Richard Gunderman, Indiana University

What do coal, viruses and DNA have in common? The structures of each the predominant power source of the early 20th century, one of the most remarkable forms of life on Earth and the master molecule of heredity were all elucidated by one person. Her name was Rosalind Franklin, and the story of her triumph over sexism and rise to scientific greatness is made even more remarkable by the fact that she lived only 37 years.

In Franklins day, sexism ran rampant in science. Her own father, judging science no career for a woman, actively discouraged her aspirations. Her doctoral supervisor at Cambridge, eventual Nobel Laureate Ronald G.W. Norrish, called her stubborn and difficult to supervise and offered little support. James Watson, whose Nobel Prize hinged in large part on her work, referred to her in his memoir as Rosy (against her preference), and stated that, because of her belligerent moods, colleagues knew she either had to go or be put in her place.

Despite the attitudes of those around her, Franklin maintained her scientific acumen and thirst for knowledge, crucially contributing to one of the greatest discoveries of the 20th century.

Franklin was born in London on July 25, 1920 to a prominent family. Her great uncle served in the British Cabinet, and her father was a banker and science educator.

Franklin was an outstanding student. She received a scholarship to Cambridge, where she earned honors on her examinations and won a research fellowship. A lack of rapport with her supervisor, Norrish, drove her from his lab, and she ended up conducting groundbreaking research for her Ph.D. thesis on the molecular structure of coal.

Franklin then moved to Paris, where she studied X-ray crystallography, a powerful means of inferring the structure of molecules from how they bend beams of X-rays. She produced a number of important articles before returning to the U.K.

[Deep knowledge, daily. [Sign up for The Conversations newsletter]

Assigned to work on the structure of DNA in her new position at Kings College London, she applied her knowledge of X-ray diffraction and created crucial images of its molecular structure. At the time, determining DNAs structure was one of sciences holy grails.

Recalling a moment in 1953, Watson described first seeing one of Franklins images of the DNA molecule, known as Photograph 51:

The instant I saw the picture my mouth fell open and my pulse began to race. The pattern was unbelievably simpler from those obtained previously. Moreover, the black cross of reflections which dominated the picture could only arise from a helical structure.

Watson and his Cambridge collaborator and eventual fellow Nobel Laureate Francis Crick were not doing laboratory research on the structure of DNA, but they were actively attempting to build a model of it. Franklins image provided them with a breakthrough. Franklin was a cautious scientist, believing that modeling should await airtight scientific evidence. But Watson and Crick were less hesitant and became convinced that their double helix model must be correct.

In 1953, when Watson and Crick announced their now famous double helix model for DNA, tensions at Kings College were driving Franklin to Birkbeck College. She joined John Bernal, an X-ray crystallographer known for promoting the careers of women.

There Franklin worked on characterizing the structure of RNA, another key information-bearing molecule in living organisms. She also studied the tobacco mosaic virus, the first virus shown to be harmful to a living organism, the tobacco plant.

During a trip to the U.S. in 1956, Franklin first noticed that she was having difficulty fitting into her clothes. Upon her return to London, she was diagnosed with ovarian cancer, the result of mutations in the DNA of her own cells. Yet she did not let her illness interfere with her work and published a half dozen or more scientific papers in both 1956 and 1957. She died in April of 1958.

Franklin faced sexism for much of her professional life in science. Watson repeatedly described her in sexist terms in The Double Helix, criticizing her choice not to emphasize her feminine qualities and her lack of even a mild interest in clothes. Moreover, he and Crick chose not to reveal the extent to which their model depended on her DNA photograph.

Even in this atmosphere, Franklin was a great scientist, as captured in this passage from her obituary, composed by her mentor, Bernal:

She was distinguished by extreme clarity and perfection in everything she undertook. Her photographs are among the most beautiful X-ray photographs of any substance ever taken. Her early death is a great loss to science.

Franklin certainly did not sink into obscurity.

One of her students, eventual Nobelist Aaron Klug, continued her work, helping to develop a new form of crystallography that relies on electrons instead of X-rays and advancing the understanding of the structure of viruses.

And of course initial skepticism about a double helix structure for DNA waned. Watson, Crick and another X-ray crystallography researcher at Kings College, Maurice Wilkins, received the Nobel Prize in Physiology or Medicine in 1962 for its identification.

Many have wondered why Franklin did not receive the Nobel Prize. First, she was never nominated, perhaps in part because of her gender. Another problem was the fact that the prize cannot be divided among more than three people, though some historians have argued that she deserved it more than Wilkins. Perhaps the most decisive reason is that Nobel Prizes are not awarded posthumously.

Franklin has been memorialized in many ways. Kings College and Cambridge University both created residence halls in her name, and Birkbeck established the Rosalind Franklin Laboratory. Her portrait now hangs next to those of Watson, Crick and Wilkins in the National Portrait Gallery in London.

And outside of Chicago is the Rosalind Franklin University of Medicine and Science, which uses photograph 51 as its logo.

Franklin saw herself less as a female scientific pioneer than as a researcher whose work should be assessed purely in the light of her scientific contributions. Although she was not focused on gender, perhaps her greatest and most enduring legacy is the many women who have been inspired by her example to pursue scientific careers.

Richard Gunderman, Chancellors Professor of Medicine, Liberal Arts, and Philanthropy, Indiana University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:

Sexism pushed Rosalind Franklin toward the scientific sidelines during her short life, but her work still shines on her 100th birthday -...

DetailsCategory: AntibodiesPublished on Wednesday, 22 July 2020 11:28Hits: 138

- $32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners -

- Registration-Enabling Phase 2 CRESTONE Study Now Enrolling Patients with Solid Tumors of Any Origin that have an NRG1 Gene Fusion -

- CRESTONE Enrollment Enhanced Through Strategic Partnerships with Next Generation Sequencing Diagnostic Providers Including Ashion Analytics, Strata Oncology, and Tempus to Advance Patient Enrollment Practices for Genomically-driven, Tumor-agnostic Clinical Trials -

NEW YORK, NY, USA I July 21, 2020 I Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the launch of the Company with a $32.5M Series A financing, initiation of the Phase 2 CRESTONE study, and new partnerships with Next Generation Sequencing diagnostic providers including Ashion Analytics, Strata Oncology, and Tempus to explore innovative models for real-time identification, patient referral, and enrollment of patients with tumors driven by rare genomic alterations. The Series A financing was led by Aisling Capital and a syndicate of investors including Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners.

"At Elevation Oncology, we envision a future in which each unique genomic testing result can be matched with a purpose-built precision medicine and bring clarity to the patient treatment journey. Focused drug development paired with open collaboration will be instrumental for our industry to fully realize the potential of precision medicine for all patients with cancer," said Shawn Leland, PharmD, RPh, Founder and Chief Business Officer of Elevation Oncology. "With our lead development program, seribantumab, and the partnerships announced today, we are taking our first steps toward this future."

Seribantumab and the Tumor-agnostic CRESTONE Study

Seribantumab is a fully human IgG2 monoclonal antibody that binds to human epidermal growth factor receptor 3 (ERBB3 or HER3). HER3 is traditionally activated through binding of its primary ligand, neuregulin-1 (NRG1). The NRG1 gene fusion is a rare genomic alteration that combines NRG1 with another partner gene to create chimeric NRG1 "fusion proteins."

Seribantumab was acquired in 2019 by Elevation Oncology, and the development program builds on prior clinical experience from over 800 patients demonstrating consistent safety and tolerability. Previous clinical trials with seribantumab did not select for tumors with an NRG1 fusion. The CRESTONE study leverages seribantumab's rational design with recent discoveries on the significance of the NRG1 gene fusion and improvements in diagnostic sensitivity. Novel preclinical data generated by Elevation Oncology demonstrating the ability of seribantumab to prevent the activation of HER3 signaling in NRG1 fusion models are supportive of CRESTONE and are expected to be released in publications and at scientific conferences later this year.

Although rare, NRG1 gene fusions are oncogenic drivers that can be found in a variety of solid tumors, including lung, pancreatic, gallbladder, breast, ovarian, colorectal, and neuroendocrine cancers, and sarcomas. Importantly, NRG1 gene fusions are mutually exclusive with other known driver mutations and are considered a unique oncogenic driver event essential for tumor cell survival. Following recent regulatory approvals of tumor-agnostic treatments associated with oncogenic drivers, CRESTONE is designed as a registration-enabling Phase 2 "basket trial" to evaluate the efficacy and safety of seribantumab in patients with any solid tumor that harbor an NRG1 fusion.

"Genomic testing and matched precision therapeutics are creating a revolution in oncology development and regulatory approval paths," said Lori Kunkel, MD, Chair of the Elevation Oncology Scientific Advisory Board and former Chief Medical Officer LOXO Oncology. "The FDA has recently approved several oncology therapeutics for tumor-agnostic indications. I am encouraged to see the evolution in our understanding of how to achieve better clinical outcomes to address the unmet clinical need among patients with a genomically defined cancer, regardless of its tissue of origin. The CRESTONE study potentially expands the actionability of genomic tests to tumors with an NRG1 fusion and is a promising approach for furthering this genomically-driven tumor-agnostic development pathway."

Innovative Models for Patient Enrollment

Sarah Cannon Research Institute(Sarah Cannon) has been selected as the first strategic site for CRESTONE and is open and enrolling patients today. Sarah Cannon's world class clinical research leadership and insights as well as additional prospectively selected clinical sites are foundational to ensuring rigorous study conduct.

"Identifying potential driver alterations, such as NRG1 gene fusions, enables us to approach cancer treatment in a more targeted way," said David Spigel, MD, Chief Scientific Officer, Sarah Cannon Research Institute at Tennessee Oncology and one of the investigators of the CRESTONE study. "Today, all cancer patients facing a treatment decision without clear standard of care should consider comprehensive genomic testing for their tumor. Collaborations across the healthcare ecosystem help to ensure that the value of each genomic test is maximized and to expand access to critical treatment opportunities for patients."

Diagnostic partnerships will enhance traditional patient enrollment in the CRESTONE study through real-time, nationwide identification of NRG1 fusion positive patients withintheAshion, Strata Oncology, Tempus, and other partner networks. Through various partnership models, patients may also be enrolled in CRESTONE through active referral to current strategic sites or "just-in-time" site initiation.

These innovative models address specific challenges encountered by genomically-driven, tumor-agnostic trials such as the rarity of genomic driver alterations and the impracticality of comprehensive clinical site coverage by both geography and organ-system of study. In addition, these models may reduce the burden on patients by minimizing the number of diagnostic tests they may need and maximizing the treatment opportunities available to them, regardless of where they may live. Bringing clinical trials to patients using the "just-in-time" site initiation model can further help to minimize travel and keep patients safe in the face of ongoing travel restrictions due to COVID-19.

"With the strong backing of a dynamic and experienced investor syndicate, Elevation Oncology is well positioned to execute on our mission of delivering precision medicines to physicians and their patients with cancer," said Steve Elms, Chairman and Interim Chief Executive Officer of Elevation Oncology and Managing Partner of Aisling Capital. "Our development approach to seribantumab sets the stage for our broader vision: the elevation of precision medicine to the forefront of every patient journey through building a collaborative industry-wide ecosystem. Together with diagnostic developers, clinical researchers, patient advocates, and the Elevation Oncology team, we are looking to build a pipeline of precision oncology medicines that can amplify each other's efforts towards our shared goal of improving patient outcomes."

About Elevation Oncology

Elevation Oncology is founded on the belief that every patient with cancer deserves to know what is driving the growth of their disease and have access to therapeutics that can stop it. We make genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Together with our peers we work towards a future in which each unique test result can be matched with a purpose-built precision medicine to enable an individualized treatment plan for each patient. Our lead candidate, seribantumab, inhibits tumor growth driven by NRG1 fusions and is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion. Details on CRESTONE are available at http://www.NRG1fusion.com. For more information visit http://www.ElevationOncology.com.

About Ashion Analytics

Ashion Analytics, LLC, is a CLIA-certified and CAP-accredited clinical laboratory that uses advanced genomic technologies to offer a wide range of testing capabilities to assist physicians, health systems, research and commercial partners to provide precision cancer treatments. Ashion was developed and launched by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope. TGen is a pioneer in the use of genomics to identify treatment options for cancer patients.

About Strata Oncology

Strata Oncology, Inc. is a precision medicine company dedicated to transforming cancer care by building a platform to systematize precision oncology across a network of health systems and biopharma companies. Strata Oncology empowers health systems to deliver a comprehensive, system-wide precision oncology program that integrates cutting-edge tumor molecular profiling and a portfolio of biomarker-guided with routine care, so that all patients with advanced cancer have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visitwww.strataoncology.com.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful, Tempus enables physicians to make real-time, data-driven decisions to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Additionally, the TIME TrialNetwork leverages a unique and comprehensive infrastructure to bring the right clinical trials to the right patients in under two weeks.The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

SOURCE: Elevation Oncology

See the original post here:

Elevation Oncology Emerges from Stealth with $32.5M Series A to Develop Precision Medicines for Tumors Harboring Rare Genetic Driver Alterations |...

ADRIAN Hill is the leading scientist among the team of researchers who are striving to develop a working vaccine for Covid-19 through clinical trials.

The Irish doctor's coronavirus vaccine has been described by WHO as the leading candidate for a working vaccine.

5

5

Here's everything we know about Dr Adrian Hill and his work to find a cure for coronavirus.

The 62-year-old doctor grew up in Ranelagh in Dublin and attended Belvedere College.

He then went on to study medicine at Trinity College and transferred to the University of Oxford in 1978 where he completed his medical degree in 1982.

5

During his time as a student in the 1980s, Dr Hill developed a fascination with vaccines and tropical diseases such as malaria.

His interest began when he visited his uncle who was a missionary priest working in a hospital during the civil war in Zimbabwe.

Adrian continued his studies in Oxford until he graduated with a Doctor of Philosophy degree in 1986.

In 1988, he joined the Weatherall Institute of Molecular Medicine at Oxford and began working on immunogenetics in West Africa.

From there he became the leader of an academic course on Human and Animal Vaccinology at Oxford and is now the Director of the Jenner Institute, an Oxford institute which develops vaccines and carries out clinical trials for diseases.

He also heads a group at the Wellcome Trust Centre for Human Genetics which studies genetic susceptibility factors for common bacterial diseases.

The Irish vaccinologist has two children with his former wife, Sunetra Guptta who is a well known Indian novelist and professor of theoretical epidemiology at the University of Oxford with an interest in infectious disease agents.

Dr Hill established his growing reputation for his work on an Ebola vaccine in 2014.

His team took the lead in the first clinical trial of an Ebola vaccine which targeted the outbreak of the disease in West Africa.

5

The team also developed malaria vaccines that have been tested in clinical trials and is one of the most promising vaccines against the disease.

Adrian is at the forefront of driving the power of medicine to provide healthcare for some of the poorest communities around the world.

In 2014, Dr Hill gave a statement saying: "Witnessing the events in Africa makes it clear that developing new drugs and vaccines against Ebola should now be an urgent priority.

"It is tremendous that so many people have worked hard to make this trial happen in short time, and I am enormously grateful to those volunteers who have come forward to take part and to the funders for supporting this trial so quickly.

"These are initial safety trials of the vaccine and it will be some time before we know whether the vaccine could protect people against Ebola. But we are optimistic that the candidate vaccine may prove useful against the disease in the future."

He has expertise in vaccines for Ebola and malaria, immunology and vaccinology of infectious diseases, human genetics particularly susceptibility to tuberculosis, leprosy, sepsis and other bacterial diseases as well as vaccines against intracellular pathogens.

Dr Hill and his team have now shifted their focused onto Covid-19 and are now the leading candidates for a working vaccine.

The Oxford Covid-19 vaccine trial is being run by the Jenner Institute and Oxford Vaccine Group.

5

While Professor Hill is leading the team, other keys members include Prof. Sarah Gilbert, Prof. Andrew Pollard, Prof. Teresa Lambe, Dr Sandy Douglas and Prof. Catherine Green.

The team began developing a vaccine against the coronavirus on January 20, 2020 and have shown great success in recent weeks.

The results of the first phase of the trial were published on Monday in The Lancet, a scientific journal, and indicate no early safety concerns and induces strong immune responses in both parts of the immune system.

The vaccine provoked a T cell response within 14 days of vaccination - this means white blood cells that can attack cells infected with the coronavirus responded within two weeks.

Additionally, there was an antibody response within 28 days - antibodies are able to neutralise the virus so that it cannot infect cells when initially contracted.

During the study participants who received the vaccine had detectable neutralising antibodies, which have been suggested by researchers as important for protection.

Scientists said it produced a reaction in people aged 18 to 55 that lasted at least two months after they were immunised.

Prof Hill said: What were reporting today is the result of a phase 1 trial in over 1,000 people looking at how well this vaccine performs both in terms of its safety, which is good and its immune responses which are pretty exciting.

Hill said that larger trials evaluating the vaccines effectiveness, involving about 10,000 people in the UK as well as participants in South Africa and Brazil are still underway.

Another big trial is hoping to start in the US soon, aiming to enroll about 30,000 people.The next step in studying the vaccine is to confirm that it can effectively protect against Covid-19 infection.

Dr Hill's vaccine will now potentially move forward to more trials where researchers will deliberately attempt to infect test subjects with the virus after they have been given a dose of the vaccine.

Oxford is working with multinational biopharmaceutical company AstraZeneca for the further development, large-scale manufacture and potential distribution of the Covid-19 vaccine.

'real heroes'Tributes paid as hero doctor sadly loses battle against Covid-19 in ICU

TRAVEL fearsTravel through airports not on green list ok if you don't leave, Coveney says

Jackpot!Lotto urge EuroMillions players to check emails as one player wins 49.5m

DEAL BLASTMicheal Martin under fire for striking 'bad deal' for EU Covid-19 rescue fund

Green Light15 countries on highly awaited Green List revealed

Latest

whopping winHunt is on to find Irish Euromillions player who won 49.5m jackpot

The project has received 84million 75million) of government funding to help accelerate the vaccines development.

The timeline for a phase three trial depends on whether enough participants have been exposed to the coronavirus in everyday life, which should reveal whether those who have received the vaccine are protected.

This can take months depending on infection levels in the community.

See more here:

Coronavirus vaccine Who is Irish scientist Adrian Hill, where did he grow up & how did he lead team to b - The Irish Sun

The New Report Titled as Nuclear Medicine or Radiopharmaceuticals Market published by Reportspedia, covers the market landscape and its evolution predictions during the forecast period. The report objectives to provide an overview of global Nuclear Medicine or Radiopharmaceuticals Market with detailed market segmentation by solution, security type, application and geography. The Nuclear Medicine or Radiopharmaceuticals Market is anticipated to eyewitness high growth during the forecast period. The report delivers key statistics on the market status of the leading market players and deals key trends and opportunities in the market.

Request For Free Sample Report: @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-nuclear-medicine-or-radiopharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58216#request_sample

This research report also includes profiles of major companies operating in the global market. Some of the prominent players operating in the Global Nuclear Medicine or Radiopharmaceuticals Market are:

Lantheus Medical Imaging, Inc.Advanced Accelerator Applications S.A.Mallinckrodt PLCBayer AGCardinal Health, Inc.Bracco Imaging S.P.AIba MolecularGE HealthcareNordion, Inc.Eczacibasi-Monrol Nuclear Products

The Nuclear Medicine or Radiopharmaceuticals Market for the regions covers North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Regional breakdown has been done based on the current and forthcoming trends in the global Nuclear Medicine or Radiopharmaceuticals Market along with the discrete application segment across all the projecting region.

Ask For Discount: https://www.reportspedia.com/discount_inquiry/discount/58216

The Type Coverage in the Market are:

Diagnostic Nuclear MedicineTherapeutic Nuclear Medicine/ Radiopharmaceuticals

Market Segment by Applications, covers:

Diagnostic ApplicationsTherapeutic Applications

Some Major TOC Points:

Chapter 1. Nuclear Medicine or Radiopharmaceuticals Market Report Overview

Chapter 2. Global Nuclear Medicine or Radiopharmaceuticals Market Growth Trends

Chapter 3. Market Share by Key Players

Chapter 4. Nuclear Medicine or Radiopharmaceuticals Market Breakdown Data by Type and Application

Chapter 5. Market by End Users/Application

Chapter 6. COVID-19 Outbreak: Nuclear Medicine or Radiopharmaceuticals Industry Impact

Chapter 7. Opportunity Analysis in Covid-19 Crisis

Chapter 9. Market Driving Force

Continue for TOC

Do you want any other requirement or customize the report, Do Inquiry Here: https://www.reportspedia.com/report/life-sciences/2015-2027-global-nuclear-medicine-or-radiopharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58216#inquiry_before_buying

Key questions Answered in this Nuclear Medicine or Radiopharmaceuticals Market Report:

What will be the Nuclear Medicine or Radiopharmaceuticals Market growth rate and value in 2020?

What are the key market predictions?

What is the major factors of driving this sector?

What are the situations to market growth?

Major factors covered in the report:

Global Nuclear Medicine or Radiopharmaceuticals Market summary

Economic Impact on the Industry

Nuclear Medicine or Radiopharmaceuticals Market Competition in terms of Manufacturers

Nuclear Medicine or Radiopharmaceuticals Market Analysis by Application

Marketing Strategy comprehension, Distributors and Traders

Study on Market Research Factors

Table of Content & Report Detail @ https://www.reportspedia.com/report/life-sciences/2015-2027-global-nuclear-medicine-or-radiopharmaceuticals-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58216#table_of_contents

See the article here:

Nuclear Medicine or Radiopharmaceuticals Market Innovative Report Growth impact over the forecast year 2020 to 2027 - Cole of Duty

The US Justice Department has charged another professor at an American university with committing research grant fraud to benefit China. Ohio State Universitys Song Guo Zheng used more than $4 million (3.2 million) in grant money from the US National Institutes of Health (NIH) to develop rheumatology and immunology expertise for the Chinese government, according to a criminal complaint unsealed following his 9 July detention hearing.

The 57-year-old Zheng has also allegedly been a participant in the Chinese governments Thousand Talents programme a scheme to recruit and cultivate high-profile scientists since 2013. He is charged with making false statements about maintaining employment in China at the same time he was working for US universities. Zheng, who was previously at the University of Southern California and Pennsylvania State University, faces up to 15 years in prison if convicted.

Zheng was arrested on 22 May at an airport in Alaska while preparing to board a flight to China. He had with him two laptops, three mobile telephones, several USB drives, several silver bars, expired Chinese passports for his family, as well as deeds for property in China, according to the Justice Department. Ohio State University spokesperson Ben Johnson says Zheng is currently on unpaid leave and that the university is proceeding towards termination. Zheng has been denied bail as he is considered a flight risk.

Yet again, we are faced with a professor at a US university, who is a member of a Chinese talent plan, allegedly and deliberately failing to disclose his relationship with a Chinese university and receipt of funds from the Chinese government in order to obtain millions of dollars in US grant money designed to benefit the health and well-being of the people of the US, said US assistant attorney general for national security, John Demers.

David DeVillers, US attorney for the Southern District of Ohio, said that this is his offices third recent case involving the illegal transfer of intellectual property and research to China.

A number of researchers in the US have faced similar charges in recent months, the most prominent being Charles Lieber, the former chair of Harvard Universitys Chemistry and Chemical Biology Department. He was indicted last month for making false statements to the authorities about his participation in the Thousand Talents programme.

Lieber allegedly concealed from both Harvard and the NIH his position as a strategic scientist at a Chinese university and the fact that the Chinese government was paying him, through the Wuhan University of Technology, a $50,000 monthly stipend, more than $150,000 in living expenses and more than $1.5 million to establish a laboratory in China. After his arrest in January, Lieber pleaded not guilty in June to two counts of making false statements.

Other lower-profile scientists have also been arrested over undeclared involvement in the Thousand Talents plan. In May, the Justice Department arrested Qing Wang, a former researcher with the Cleveland Clinic who worked on molecular medicine and the genetics of cardiovascular disease, and Simon Saw-Teong Ang, a University of Arkansas scientist conducting research for Nasa. Both were allegedly committing fraud by concealing their participation in Chinese talent recruitment programmes while accepting millions of dollars in American federal grant funding, said the director of the Federal Bureau of Investigation (FBI), Christopher Wray, during remarks earlier this month to the Hudson Institute, a conservative thinktank in Washington DC.

Other cases include those of former Emory University neuroscientist Xiao-Jiang Li who pled guilty to filing a fraudulent tax return in May after failing to report income hed received through the Thousand Talents programme. Wray said the FBIs investigation found that while Li was researching Huntingtons disease at Emory, he also received half a million dollars from China which he never reported. In March, James Patrick Lewis, who at the time was a physics professor at West Virginia University, pled guilty to defrauding his institution so that he could take leave to satisfy competing obligations to a Chinese one. He was a tenured professor at the university between 2006 and August 2019, and specialised in coal conversion technologies.

Data presented to the advisory committee to the NIH director in June revealed that 54 researchers have resigned or been fired as a result of the NIHs investigation into whether grant recipients are properly disclosing foreign ties. The report found that 133 grant recipients had an undisclosed foreign grant and 102 had an undisclosed talent award. Consequently, 77 of these researchers have been removed from the NIH system 41% of the 189 scientists who the agency investigated. Nearly all of those cases under review 93% involve Chinese funding.

More here:

Criminal charges for undeclared Chinese research ties mount in the US - Chemistry World

SARASOTA, Fla., July 21, 2020 /PRNewswire/ --Lakewood-Amedex Therapeutics, Inc. Inc. (the "Company"), a clinical-stage development company of revolutionary antimicrobial Bisphosphocin pharmaceuticals for rapid localized treatment of serious antibiotic-resistant and antifungal infections, today announced that Peter B. Corr, Ph.D., has been elected as Chairman of the Board of Directors of the company. Dr. Corr assumes the role from Steve Parkinson, who continues to serve as President and CEO.

Dr. Corr, a pharmaceutical industry veteran of more than 26 years, will help guide the company as it completes a private financing underway and advances its clinical programs using antimicrobial Bisphosphocins for the treatment of serious infections of the lungs, bladder, skin and other tissues, including those caused by antibiotic-resistant bacteria, yeast and fungi.

Dr. Corr, who untilDecember 2006, served as Senior Vice President for Science and Technology of Pfizer Inc., and also headed up worldwide pharmaceutical research and development for Pfizer, previously served as Executive Vice President, Pfizer Global Research & Development and President, Worldwide Development. He also served as Senior Vice President, Discovery Research, at Monsanto/Searle and then, President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.

Dr. Corr isCo-Founder and Managing General Partner of Auven Therapeutics Management LLLP., and was Chairman of the Board of Directors for ADC Therapeutics, S.A., founded by Auven, from its inception in 2011 through the completion of its upsized $267 million initial public offering in May, 2020. Dr. Corr is Founder and Chairman of the Board of Imvax Inc., a research and development company focused on cancer with an initial emphasis on glioblastoma and other solid tumors.

In addition, Dr. Corr has served as Chairman of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); Chairman of the PhRMA Foundation Board of Directors; and Chairman of the Hever Group for six years, representing Chief Scientific Officers (CSO's) across the European and U.S. based pharmaceutical industry. He is a former Governor of the New York Academy of Sciences (and previous Chairman of the Board of Governors). Additionally, he was Chairman of the Board of the International Partnership for Microbiocides and Chairman of the Board of Directors for the Critical Path Institute. He served as a founding member of the Board of Directors of Furiex Pharmaceuticals, Inc., until the sale of the company in 2014. He is a Founder and Chairman Emeritus of the Board of Patient Assist VI which provides medicines to indigent patients in the U.S. Virgin Islands. He currently serves on the National Council for Washington University School of Medicine.

Dr. Corr received his doctorate from Georgetown University School of Medicine and spent 18 years as a researcher in molecular biology and pharmacology at Washington University, St. Louis, ultimately becoming Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts. Dr. Corr is the recipient of numerous awards and honors.

Steve Parkinson, President and CEO of Lakewood-Amedex, commented, "We are excited to have such an accomplished industry veteran of Dr. Corr's stature assume the role of Chairman of Lakewood-Amedex Therapeutics. Dr. Corr's great experience in three major pharmaceutical companies, now all part of Pfizer, means he truly understands the growing problem of microbial resistance and the need for new antimicrobials and antifungals to fight this major threat. Dr. Corr will certainly guide us in the right direction."

Dr. Corr commented, "I have long recognized, and can't overstate, the importance of bringing novel antimicrobial products to market to fight the growing threat from antimicrobial resistance. I have been helping the Company over the last 18 months due to the importance of their work. I look forward to working formally with the team at Lakewood-Amedex to advance the exciting clinical pipeline of Bisphosphocin products and to establishing the company as a leader in the field. The developments being made at Lakewood-Amedex will, I believe, be of immense importance to the world, as evidenced recently, by the $1 billion commitment of several major pharmaceutical companies to this area."

About Lakewood-Amedex Therapeutics Inc.Lakewood-Amedex Therapeutics is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The company's products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets. The company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and fungi and has recently completed a Phase 2 clinical trial in patients with infected diabetic foot ulcers.

ContactsTiberend Strategic Advisors, Inc.InvestorsMiriam Miller(212) 375-2694mmiller@tiberend.com

MediaJohanna Bennett(212) 375-2686jbennett@tiberend.com

View original content:http://www.prnewswire.com/news-releases/lakewood-amedex-therapeutics-announces-the-election-of-peter-b-corr-phd-as-chairman-of-the-board-of-directors-301096778.html

SOURCE Lakewood-Amedex Inc.

Excerpt from:

Lakewood-Amedex Therapeutics Announces the Election of Peter B. Corr, Ph.D., as Chairman of the Board of Directors - BioSpace

The global Molecular Biomarkers Industry market has been analyzed by the researchers for a definite forecast period of 2020 to 2025. This analysis was conducted with the objective of gaining insights in the functioning of the market and aid better, easier, and faster decision-making. This report includes a detailed study of various market segments, a regional analysis, competitive analysis, as well as various market dynamics impacting the growth trajectory of the market over the forecast period. However, at the beginning of the report, the researchers have inculcated a basic overview section defining the product, its classification, and primary applications in various industry verticals to provide a better context for the report. Considering COVID-19, Molecular Biomarkers Industry market report provides comprehensive and in-depth analysis on how the epidemic push this industry transformation and reform.

The research report on Molecular Biomarkers Industry market assesses ongoing market trends, as well as the factors that are poised to enhance the market growth during the analysis timeframe. It also encompasses major market restraints which may hamper the market growth. Going on, the report also comprises of the key manufacturers which formulate the competitive terrain of the Molecular Biomarkers Industry market and also highlights the major market segmentations.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/23278

Analyzing the competitive landscape of Molecular Biomarkers Industry market:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/23278

Summary of the geographical landscape of the Molecular Biomarkers Industry market:

Additional features of the Molecular Biomarkers Industry market report:

Years considered for this report:

Historical Years: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2020-2025

The report answers key questions such as:

What is the estimated size of the market by 2025?

What are the key market trends?

Which segment is expected to account the largest market share by 2025?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

Which region accounts for a dominant share of the market?

Table of Content:

1 Molecular Biomarkers Industry market Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Molecular Biomarkers Industry market

1.4 Methodology of The Study

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Molecular Biomarkers Industry market

1.4 Methodology of The Study

1.5 Research Data Source

2 Executive Summary

3 Industry Chain Analysis

4 Global Molecular Biomarkers Industry market, by Type

5 Molecular Biomarkers Industry market, by Application

6 Global Molecular Biomarkers Industry market Analysis by Regions

7 North America Molecular Biomarkers Industry market Analysis by Countries

8 Europe Molecular Biomarkers Industry market Analysis by Countries

9 Asia Pacific Molecular Biomarkers Industry market Analysis by Countries

10 Middle East and Africa Molecular Biomarkers Industry market Analysis by Countries

11 South America Molecular Biomarkers Industry market Analysis by Countries

12 Molecular Biomarkers Industry market Competitive Landscape

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/23278

Go here to read the rest:

Outlook on the Molecular Biomarkers Market to 2025 by Application, End-user and Geography - CueReport

The globalMolecular Microbiology Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Molecular Microbiology market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Molecular Microbiology market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Molecular Microbiology market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Molecular Microbiology market.

Leading players of the global Molecular Microbiology market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Molecular Microbiology market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Molecular Microbiology market. It also provides useful recommendations for new as well as established players of the global Molecular Microbiology market.

Request sample copy of this report:https://www.reporthive.com/request_sample/2382217

Major Players:

RocheQiagenIlluminaAbbottHologicBioMerieuxDanaher (Cepheid)Myriad GeneticsDAAN GeneAgilentGenomic HealthBDFoundation Medicine

Segmentation by Product:

Quantitative PCR Detection Diagnostic KitsPathogenic Microorganisms Diagnostic Kits

Segmentation by Application:

HumanVeterinary

Regions and Countries:U.S, Canada, France, Germany, UK, Italy, Rest of Europe, India, China, Japan, Singapore, South Korea, Australia, Rest of APAC, Brazil, Mexico, Argentina, Rest of LATAM, Saudi Arabia, South Africa, UAE.

Report Objectives

Table of Contents

Report Overview:It includes major players of the global Molecular Microbiology market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Molecular Microbiology market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Molecular Microbiology market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Molecular Microbiology market by application, it gives a study on the consumption in the global Molecular Microbiology market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Molecular Microbiology market are profiled in this section. The analysts have provided information about their recent developments in the global Molecular Microbiology market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Molecular Microbiology market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Molecular Microbiology market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Molecular Microbiology market.

Key Findings:This section gives a quick look at important findings of the research study.

Request for Customization:https://www.reporthive.com/request_customization/2382217

About us:

Our research base consists of a wide spectrum of premium market research reports. Apart from comprehensive syndicated research reports, our in-house team of research analysts leverages excellent research capabilities to deliver highly customized tailor-made reports. The market entry strategies presented in our reports has helped organizations of all sizes to generate profits by making timely business decisions. The research information including market size, sales, revenue, and competitive analysis offered, is the product of our excellence in the market research domain.

See original here:

COVID-19 Impact ON Molecular Microbiology Market : What are the top drivers and challenges? - 3rd Watch News

Why are newborns born to mothers with COVID-19 rarely infected? Researchers at the Wayne State University School of Medicine and the Perinatology Research Branch of National Institute of Child Health and Human Development/National Institutes of Health in Detroit have found that placental cells minimally express the instructions, or mRNA, to generate the cell entry receptor and protease required by the virus that causes COVID-19 to invade human cells.

The pandemic caused by SARS-CoV-2 has infected more than 10 million people worldwide, including pregnant women, yet to date there is no consistent evidence that pregnant mothers pass the virus to their newborns.

While pregnant women represent a potential high-risk population given that other viral infections such as Zika, cytomegalovirus and rubella can be passed from mother to fetus, the evidence for vertical transmission of SARS-CoV-2 is rare, and acquisition of the virus in the nursery cannot be excluded.

A requirement for a virus to infect a cell is that cell surface expresses a receptor for the virus. The main receptor for the new coronavirus is the angiotensin converting enzyme 2, or ACE2. The spike protein of the virus the spikes seen in the images of the virus is activated by an enzyme called TMPRSS2. Cells that co-express ACE2 and TMPRSS2 such as those found in the lungs are particularly vulnerable to infection.

In the study Does the human placenta express the canonical cell entry mediators for SARS-CoV-2?, published today in the journal eLife,WSU and PRB researchers employed cutting-edge molecular techniques such as single-cell genomics to determine whether human placental cells express the mRNA for the mediators that the virus SARS-CoV-2 uses for entry into the cell. The researchers concluded that placental cells do not express the transcripts needed to develop the receptors that the virus requires to facilitate vertical transmission from mother to the fetus.

The findings of this study help to understand why mother-to-fetus transmission is so rare (less than 2% of cases), said Roberto Romero, M.D., D.Med.Sci, chief of the PRB. The most likely explanation is that the cellular instructions for the production of the main receptor for SARS-CoV-2 are not expressed in the human placenta. In contrast, the receptors for other viruses known to cause fetal infection such as Zika and cytomegalovirus were found in placental cells.

Roger Pique-Regi, Ph.D., assistant professor of the WSU Center for Molecular Medicine and Genetics, and of Obstetrics and Gynecology, first author of the study, explained that the single-cell genomics technology the researchers employed allows them to study the transcriptome of individual cells isolated in tiny oil droplets using microfluidics.

This allows us to obtain at an unprecedented level of detail the multiple different cell types and the genes being expressed in gestational tissues, said Dr. Pique-Regi, head of the Single-Cell Genomics Section of the PRB. Here, we have dissected at the molecular level the different cell types of the human placenta across trimesters, and the membranes enveloping the fetus in the third trimester. This allowed us to determine which cell types are present and if they express the genes necessary for viral infection and spreading.

While the study allows the possibility that SARS-CoV-2 could infect the placenta via alternate entry routes while interacting with other proteins, the findings provide strong evidence that it is unlikely to infect the placenta and fetus through the traditional cell entry mediators.

Single-cell and single-nucleus RNA sequencing allowed us to investigate the expression of the main cell entry mediators for SARS-CoV-2 by the human placenta throughout pregnancy, said Nardhy Gomez-Lopez, Ph.D., associate professor of the WSU Department of Obstetrics and Gynecology and head of the Immunobiology Section of the PRB. Our findings revealed that the human placenta lacks expression of such mediators, providing an explanation for the paucity of vertical transmission in pregnant women with COVID-19. Yet, placental cells do express the receptors for other viruses such as Zika, cytomegalovirus and rubella, explaining why some infections affect the fetus and others are unlikely to do so.

Other members of the research team include Adi Tarca, Ph.D., professor of WSU Obstetrics and the Gynecology, Bioinformatics and Computational Biology Unit of the WSU School of Medicine Perinatal Initiative; Francesca Luca, Ph.D., associate professor of WSU Molecular Medicine and Genetics, and of Obstetrics and Gynecology; Yi Xu, PRB research associate; Adnan Alazizi, Center for Molecular Medicine and Genetics researcher; Yaozhu Leng, PRB research assistant; and Chaur-Dong Hsu, M.D., chair and Frank P. Iacobell Professor of WSU Obstetrics and Gynecology.

A video of the study is available here.

Visit link:

Research team finds reason mothers rarely pass COVID-19 virus to fetus - The South End

Podium Presentation Accepted for the American Society of Cytopathology (ASC) Annual Meeting

PARSIPPANY, NJ, July 21, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that a peer-reviewed manuscript describing results from a seminal clinical validation study of the combination of ThyGeNEXT and ThyraMIR has been accepted for publication in the highly respected journal, Diagnostic Cytopathology. The study, led by Dr. Mark Lupo from the Thyroid and Endocrine Center of Florida, reported on the ability of the combination of ThyGeNEXT/ThyraMIR tests to successfully stratify nearly 200 indeterminate thyroid nodules for risk of malignancy. Sites participating in this multicentered study included Cedars-Sinai Medical Center, Jackson Thyroid & Endocrine Clinic, University of Michigan, Massachusetts General Hospital/Harvard Medical School, and the University of Arkansas for Medical Sciences.

According to Jack Stover, President and CEO of Interpace, Were excited that this important study will soon be published in such a prominent peer reviewed journal and will be further highlighted at the ASC Annual Meeting in November. He continued We look forward to sharing these results with the physician and payer communities shortly.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT is Interpaces most recent next generation sequencing test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer.

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and Commercial insurers, with more than 280 million members covered.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

About ASC

The American Society of Cytopathology (ASC), founded in 1951, is a 3,000 member distinguished national professional society of physicians, cytotechnologists and scientist who are dedicated to the cytologic method of diagnostic pathology. The ASCs diverse membership includes representatives from other countries who share a vision of education, research and continuous improvement in the standards and quality of patient care. The ASC is a unique society that provides a forum where physicians and cytotechnologists can interact and network with each other on both a personal and professional level.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement, including the adverse impact of the Coronavirus (COVID-19) pandemic, our history of operating losses and the limited revenue generated by our clinical and pharma services customers, our dependence on sales and reimbursements from our clinical services, our reliance on third parties to process and transmit claims to payers for our clinical services, and any delay, data loss, or other disruption in processing or transmitting such claims could have an adverse effect on our revenue and financial condition, our revenue recognition being based in part on our estimates for future collections which estimates may prove to be incorrect, that we will be able to meet our revenue projections and that there is no guarantee that we will be successful in completing development or realize any revenue or benefit from our efforts to launch a new product line of antibody testing of the COVID-19 virus. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor RelationsEdison Group Joseph Green(646) 653-7030 jgreen@edisongroup.com

Go here to see the original:

Interpace Announces Acceptance of Seminal Clinical Validation Study for Thyroid Assays - GlobeNewswire

SARASOTA, Fla., July 21, 2020 /PRNewswire/ --Lakewood-Amedex Therapeutics Inc. (the "Company"), a clinical-stage development company of revolutionary antimicrobial Bisphosphocin pharmaceuticals for rapid localized treatment of serious antibiotic-resistant and antifungal infections, today announced that Peter B. Corr, Ph.D., has been elected as Chairman of the Board of Directors of the company. Dr. Corr assumes the role from Steve Parkinson, who continues to serve as President and CEO.

Dr. Corr, a pharmaceutical industry veteran of more than 26 years, will help guide the company as it completes a private financing underway and advances its clinical programs using antimicrobial Bisphosphocins for the treatment of serious infections of the lungs, bladder, skin and other tissues, including those caused by antibiotic-resistant bacteria, yeast and fungi.

Dr. Corr, who untilDecember 2006, served as Senior Vice President for Science and Technology of Pfizer Inc., and also headed up worldwide pharmaceutical research and development for Pfizer, previously served as Executive Vice President, Pfizer Global Research & Development and President, Worldwide Development. He also served as Senior Vice President, Discovery Research, at Monsanto/Searle and then, President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis.

Dr. Corr isCo-Founder and Managing General Partner of Auven Therapeutics Management LLLP., and was Chairman of the Board of Directors for ADC Therapeutics, S.A., founded by Auven, from its inception in 2011 through the completion of its upsized $267 million initial public offering in May, 2020. Dr. Corr is Founder and Chairman of the Board of Imvax Inc., a research and development company focused on cancer with an initial emphasis on glioblastoma and other solid tumors.

In addition, Dr. Corr has served as Chairman of the Science & Regulatory Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA); Chairman of the PhRMA Foundation Board of Directors; and Chairman of the Hever Group for six years, representing Chief Scientific Officers (CSO's) across the European and U.S. based pharmaceutical industry. He is a former Governor of the New York Academy of Sciences (and previous Chairman of the Board of Governors). Additionally, he was Chairman of the Board of the International Partnership for Microbiocides and Chairman of the Board of Directors for the Critical Path Institute. He served as a founding member of the Board of Directors of Furiex Pharmaceuticals, Inc., until the sale of the company in 2014. He is a Founder and Chairman Emeritus of the Board of Patient Assist VI which provides medicines to indigent patients in the U.S. Virgin Islands. He currently serves on the National Council for Washington University School of Medicine.

Dr. Corr received his doctorate from Georgetown University School of Medicine and spent 18 years as a researcher in molecular biology and pharmacology at Washington University, St. Louis, ultimately becoming Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts. Dr. Corr is the recipient of numerous awards and honors.

Steve Parkinson, President and CEO of Lakewood-Amedex, commented, "We are excited to have such an accomplished industry veteran of Dr. Corr's stature assume the role of Chairman of Lakewood-Amedex Therapeutics. Dr. Corr's great experience in three major pharmaceutical companies, now all part of Pfizer, means he truly understands the growing problem of microbial resistance and the need for new antimicrobials and antifungals to fight this major threat. Dr. Corr will certainly guide us in the right direction."

Dr. Corr commented, "I have long recognized, and can't overstate, the importance of bringing novel antimicrobial products to market to fight the growing threat from antimicrobial resistance. I have been helping the Company over the last 18 months due to the importance of their work. I look forward to working formally with the team at Lakewood-Amedex to advance the exciting clinical pipeline of Bisphosphocin products and to establishing the company as a leader in the field. The developments being made at Lakewood-Amedex will, I believe, be of immense importance to the world, as evidenced recently, by the $1 billion commitment of several major pharmaceutical companies to this area."

About Lakewood-Amedex Therapeutics Inc.Lakewood-Amedex Therapeutics is a clinical stage pharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class antimicrobial compounds. The company's products and technology are covered by an extensive patent portfolio consisting of granted and/or issued patents and pending patent applications covering many major pharmaceutical markets. The company's lead therapeutic candidate is a novel synthetic broad-spectrum antimicrobial proven to be effective in killing a wide range of Gram-positive, Gram-negative and antibiotic-resistant bacteria and fungi and has recently completed a Phase 2 clinical trial in patients with infected diabetic foot ulcers.

ContactsTiberend Strategic Advisors, Inc.InvestorsMiriam Miller(212) 375-2694[emailprotected]

MediaJohanna Bennett(212) 375-2686 [emailprotected]

SOURCE Lakewood-Amedex Inc.

The rest is here:

Lakewood-Amedex Therapeutics Announces the Election of Peter B. Corr, Ph.D., as Chairman of the Board of Directors - PRNewswire

San Francisco, CA (UroToday.com) -- Black men in the United States are known to suffer disproportionately from prostate cancer, but few studies have investigated whether genetic differences in prostate tumors could have anything to do with these health disparities.

Now, in the largest study of its kind to date, researchers from BUSM, UC San Francisco (UCSF), and Northwestern University have identified genes that are more frequently altered in prostate tumors from men with African ancestry compared to other racial groups, though the reasons for these differences is not known, the authors say. None of the individual tumor genetic differences that were identified are likely to explain significant differences in health outcomes or to prevent Black patients from benefiting from a new generation of precision prostate cancer therapies, the authors say, as long as the therapies are applied equitably.

The newly identified gene variants could potentially lead to precision prostate cancer therapies specifically focused on men with African ancestry, and will inform broader efforts by the National Cancer Institutes RESPOND study to link gene variants to health outcomes in an even larger cohort of Black patients nationwide.

Despite declines in mortality related to cancer in the U.S., disparities by race have persisted. One in every six Black Americans will be diagnosed with prostate cancer in their lifetime, and these men are twice as likely to die from the disease as men of other races. But it is not yet clear to researchers whether differences in prostate cancer genetics contribute to these health disparities in addition to the social and environmental inequities known to drive poorer health outcomes across the board.

To date, studies trying to figure out what genes are commonly mutated in prostate cancers often have had very few samples from racial/ethnic minority groups despite the greater burden of prostate cancer in these populations. In May, the FDA approved a class of drugs known as PARP inhibitors as a therapy for men with prostate cancers driven by specific genetic mutations, but it is not known how prevalent these mutations are in people with African ancestry. As more genetic health studies are performed in minority populations, it has become clear that other genetically targeted therapies that have been developed based on studies of predominantly white patients are at times much less effective, and in some cases cause dangerous side-effects, in other racial and ethnic groups.

In the new study, published online July 10, 2020 in Clinical Cancer Research, a journal of the American Association for Cancer Research, the research team set out to better understand differences in the mutations driving prostate cancer tumors in Black versus white patients, and whether any such differences could influence disease outcomes or the effectiveness of PARP inhibitors or other targeted therapies.

The researchers collected and analyzed DNA sequencing data from previously published studies and from a commercial molecular diagnostics company. In total, they examined mutational patterns in prostate cancers from more than 600 Black men, representing the largest such study of this population to date.

The team found that the frequency of mutations in DNA repair genes and other genes that are targets of current therapeutics are similar between the two groups, suggesting that at least these classes of current precision prostate cancer therapies should be beneficial in people of both African and European ancestry, according to corresponding author Franklin Huang, MD, PhD, an assistant professor in UCSFs Division of Hematology/Oncology and member of the UCSF Helen Diller Family Comprehensive Cancer Center, UCSF Institute for Human Genetics, and UCSF Bakar Computational Health Sciences Institute.

While the researchers found no significant differences in frequencies of mutations in genes important for current prostate cancer therapies, they did identify other genes, such as ZFXH3, MYC, and ETV3, that were more frequently mutated in prostate cancers from Black men.

Developing a comprehensive understanding of how tumor genomics and other biological factors interact with social and environmental inequities to drive poorer clinical outcomes for Black prostate cancer patients should be an important priority for the efforts to improve precision medicine for these patients, the researchers say.

These types of studies will remain important to understand when certain therapies may preferentially benefit Black patients, who continue to remain underrepresented in clinical trials, Dr. Campbell said.

In particular, the results will inform the efforts of the NCI-funded RESPOND Study. RESPOND provided funding for the new UCSF-BUSM-Northwestern study to guide its efforts to perform targeted gene sequencing in tumors from an even larger cohort of Black prostate cancer patients, said Huang, who leads RESPONDs tumor genetics studies based at UCSF. Through partnerships with Black communities across the country, RESPOND aims to recruit 10,000 Black prostate cancer patients in an effort to better understand the drivers of the diseases outsize burden among Black Americans.

Previous studies have looked in isolation at different biological, social and environmental drivers of well-known racial disparities in prostate cancer, Dr. Huang said. RESPOND is a nationwide effort to integrate all these components and ultimately identify specific steps that can be taken to eliminate prostate cancers unequal burden in Black communities.

Authors: The studys lead authors are Yusuke Koga of BUSM, Hanbing Song of UCSF, and Zachary Chalmers of Northwestern University. Additional authors are Elad Ziv of UCSF; Justin Newberg and Garrett M. Frampton of Foundation Medicine, in Cambridge; Eejung Kim and Daphnee Piou of the Broad Institute of MIT and Harvard; Jian Carrot-Zhang and Matthew Meyerson of the Broad Institute and Dana-Farber Cancer Institute; Paz Polak of Mt. Sinai School of Medicine in New York; and Sarki Abdulkadir of Northwestern University.

Funding: The study was supported by the U.S. Department of Defense (W81XWH-17-PCRP-HD); the U.S. National Institutes of Health (NIH) National Cancer Institute (NCI) (P20 CA233255-01, U19 CA214253); and the Prostate Cancer Foundation.

Source: "Largest-Ever Study Of Prostate Cancer Genomics In Black Patients Ids Potential Targets For Precision Therapies | School Of Medicine". 2020.Bumc.Bu.Edu.

Related Content:

Genomic Profiling of Prostate Cancers from Men with African and European Ancestry.

Read more from the original source:

Largest-Ever Study of Prostate Cancer Genomics in Black Patients IDs Potential Targets for Precision Therapies - UroToday

SYDNEY and LOS ANGELES, July 21, 2020 /PRNewswire/ --Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, and ImaginAb, Inc., a company that harnesses the specificity of monoclonal antibodies, have entered into a collaboration agreement to develop new targeted theranostic (diagnostic and therapy) products for a broad range of cancer types.

Clarity and ImaginAb will combine their proprietary technologies to develop novel minibody and cys-diabody radiopharmaceutical products using Clarity's copper chelators to fully exploit the benefits of the theranostic pairing of copper-64 or copper-67.

ImaginAb's CEO, Ian Wilson, said, "ImaginAb designs and engineers small, highly targeted proteins known as minibodies and cys-dibodies coupled with radioisotopes to image important molecular targets using standard Positron Emission Tomography (PET). We are excited to work together with Clarity on expanding the utility of ImaginAb's technologies and entering the field of targeted radiotherapy."

Dr Alan Taylor, Clarity's Executive Chairman, commented, "This collaboration will enable us to bring together ImaginAb's unique expertise in designing minibodies, which are used to ensure rapid and highly specific targeting of tumours, with Clarity's chelator technology, which will allow us to fully exploit the perfect pairing of copper-64 for diagnosis and copper-67 for therapy."

"The teams at Clarity and Imaginab are already working together to explore the synergies of combining their expertise in lead generation, manufacture, regulatory frameworks and clinical development to fast-track new theranostic products which will be the future of therapy. Combined, the companies will pursue their ultimate goal of developing better treatments for children and adults with cancer", Dr Taylor added.

About Clarity Pharmaceuticals

Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.

http://www.claritypharmaceuticals.com

About ImaginAb

ImaginAb Inc. is an immuno-oncology imaging company focused on providing actionable insight into patient selection and treatment progress for cancer immunotherapy, enabling precision medicine. ImaginAb engineers antibody fragments called minibodies that maintain the exquisite specificity of full-length antibodies while remaining biologically inert in the body. Used with widely available PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity. ImaginAb is advancing a pipeline of minibodies against oncology and immunology targets including the CD8 ImmunoPET targeting CD8 cells. ImaginAb's products have the potential to improve patient care and lower healthcare costs. The Company is backed by top tier venture capital firms and strategic corporate firms including The Parker Institute for Cancer Immunotherapy , Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.

For more information about ImaginAb's pipeline and technology, visit http://www.imaginab.com.

SOURCE Clarity Pharmaceuticals

http://www.claritypharmaceuticals.com

Read more:

Clarity Pharmaceuticals and ImaginAb to Collaborate on New Cancer Targets - PRNewswire

Coronavirus pandemic has been defeated in other nations but not in America. CDC needs White House to provide the leadership, says Dr. David Satcher. USA TODAY

Sweden's approach to COVID has led to death, grief and suffering. The only example we're setting is how not to deal with a deadly infectious disease.

Sweden has often been considered a leader when it comes to global humanitarian issues, regarded as a beacon of light in areas such asaccepting refugees and working against global warming. In the COVID-19 pandemic, Sweden has also created interest around the world by following its own path of using a soft approach not locking down, introducing mostly voluntary restrictions and spurning the use of masks.

This approach has been perceived as more liberal and has shown up in Be Like Sweden signs and chants at U.S. protests.Wherever measures have been lenient, though, death rates have peaked. In the United States, areas that are coming out of lockdown early are suffering, and we are seeing the same in other countries as well.

The motives for the SwedishPublic Health Agency's light-touch approach are somewhat of a mystery. Some other countries that initially used this strategy swiftly abandoned it as the death toll began to increase, opting instead for delayed lockdowns. But Sweden has been faithful to its approach.

Why? Gaining herd immunity, where large numbers of the population (preferably younger) are infected and thereby develop immunity, has not been an official goal of the Swedish Public Health Agency. But it has said immunity in the population could help suppress the spread of the disease, and some agency statements suggest it is the secret goal.

Further evidence of this is thatthe agency insists on mandatory schooling for young children, the importance of testing has been played down for a long time, the agency refused to acknowledge the importance of asymptomatic spread of the virus (concerningly, it hasencouraged those in households withCOVID-19 infected individuals to go to work and school) and still refuses to recommend masks in public, despite the overwhelming evidence of their effectiveness. In addition, the stated goal of the Swedish authorities was always not to minimize the epidemic, but rather slow it down, so that the health care system wouldnt be overwhelmed.

People outside a restaurant without masks or social distancing on July 17, 2020 in Gotland, Sweden.(Photo: Martin von Krogh/Getty Images)

Several authorities, including the World Health Organization, have condemned herd immunity as a strategy. "It can lead to a very brutal arithmetic that does not put people and life and suffering at the center of that equation, Dr. Mike Ryan, executive director of WHO'sHealth Emergencies Program, said at a press conference in May.

With COVID-19, dont only focus on death: Too many Americans are alive and in misery.

Regardless of whetherherd immunity is a goal or a side effect of the Swedish strategy, how has it worked out? Not so well, according to the agencys own test results. The proportion of Swedes carrying antibodies is estimated to beunder 10%, thus nowhere near herd immunity. And yet, the Swedish death rate is unnerving. Sweden has a death toll greater than the United States: 556 deaths per million inhabitants,compared with 425, as of July 20.

Sweden also has a death toll more than four and a half times greater than that of the other four Nordic countries combined more than seven times greater per million inhabitants. For a number of weeks, Sweden has been among the top in the world when it comes to current reported deaths per capita. And despite this, the strategy in essence remains the same.

It is possible that the Public Health Authority actually believed that the Swedish approach was the most appropriate and sustainable one, and that the other countries, many of which went into lockdown, would do worse. Perhaps this, and not herd immunity, is the main reason the authorities are desperately clinging to their strategy. Or perhaps an unwillingness to admit early mistakes and take responsibility for thousands of unnecessary deaths plays into this resistance to change. Nevertheless, the result at this stage is unequivocal.

Social distancing matters. Here is how to do it and how it can help curb the COVID-19 pandemic. USA TODAY

Adopting the Swedish model: Coronavirus doesn't care about public opinion and it still kills

We do believe Sweden can be used as a model, but not in the way it was thought of initially. It can instead serve as a control group and answer the question of how efficient the voluntary distancing and loose measures in Sweden are compared to lockdowns, aggressive testing, tracing and the use of masks.

In Sweden, the strategy has led to death, grief and suffering and on top of that there are no indications that the Swedish economy has fared better than in many other countries. At the moment, we have set an example for the rest of the world on how not to deal with a deadly infectious disease.

In the end, this too shall pass and life will eventually return to normal. New medical treatments will come and improve the prognosis. Hopefully there will be a vaccine. Stick it out until then. And dont do it the Swedish way.

Sigurd Bergmann, Ph.D., Emeritus Professor, Norwegian University of Science and Technology

Dr. Leif Bjermer. Ph.D., Professor, Respiratory Medicine and Allergology, Lund University

Barbara Caracciolo, Ph.D., in Epidemiology

Marcus Carlsson, Ph.D., Associate Professor of Mathematics, Lund University

Dr. Lena Einhorn, Ph.D., in Virology

Dr. Stefan Einhorn, Ph.D.,Professor of Molecular Oncology, Karolinska Institutet

Andrew Ewing, Ph.D., Professor of Chemistry and Molecular Biology, University of Gothenburg

Dr. Manuel Felices, Ph.D.,Head of Endocrine Surgery, NL Hospital

Dr. Jonas Frisn, Ph.D.,Professor of Stem Cell Research, Karolinska Institutet

Marie Gorwa, Ph.D., Professor of Microbiology, Lund University

Dr. ke Gustafsson, Ph.D.,Clinical Microbiology, Uppsala University Hospital

Dr. Olle Isacsson, Ph.D., Professor of Endocrinology, University of Gothenburg

Dr. Claudia Hanson, Ph.D., Associate professor, Global public health, Karolinska Institutet

Dr. Stefan Hanson, Ph.D., International Health, Karolinska Institutet.

Dr. Jan Ltvall, Ph.D., Professor of Clinical Allergy, University of Gothenburg

Dr. Bo Lundbck, Ph.D.,Professor of Epidemiology of Respiratory Diseases, University of Gothenburg

ke Lundkvist,Ph.D., Professor of Virology, Uppsala University

Dr. Cecilia Sderberg-Nauclr, Ph.D.,Professor of Microbial Pathogenesis, Karolinska Institutet

Finn Nilson, Ph.D., Associate Professor of Risk Management, Karlstad University

Andreas Nilsson, Ph.D., Professor of Psychology, University of Gothenburg

Dr. Bjrn Olsen, Ph.D., Professor of Infectious Diseases, Uppsala University

Jens Stilhoff Srensen, Ph.D., Associate Professor, School of Global Studies, University of Gothenburg

Jakob Svensson, Ph.D., Scientific Data Analysis, Max Planck Institute, Greifswald

Dr. Anders Vahlne, Ph.D., Professor of Clinical Virology, Karolinska Institutet

Dr. Anders Wahlin, Ph.D., Professor Emeritus of Hematology, University of Ume

Autoplay

Show Thumbnails

Show Captions

Read or Share this story: https://www.usatoday.com/story/opinion/2020/07/21/coronavirus-swedish-herd-immunity-drove-up-death-toll-column/5472100002/

Read this article:

Sweden hoped herd immunity would curb COVID-19. Don't do what we did. It's not working. - USA TODAY

NEW YORK A long-standing development effort has come to fruition for Cepheid which this week debuted its 10-color molecular diagnostic testing technology in a new assay to help diagnose and profile extensively drug-resistant tuberculosis and select the best treatment.

Developed in collaboration with researchers at Rutgers University and with guidance and support from the Foundation for Innovative New Diagnostics, the test is now CE-IVD marked and the Danaher subsidiary said it expects to roll it out with assistance from FIND and the World Health Organization.

360Dx Premium gives you: Full site access Interest-based email alerts Access to archives Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?Login Now.

*Before your trial expires, well put together a custom quote with your long-term premium options.

Excerpt from:

Cepheid Debuts 10-Color Molecular Detection Technology With New Tuberculosis Test - 360Dx

TB vaccine averts severe infections, deaths from Covid-19: Study - india news - Hindustan Times "; forYoudata += ""; forYoudata += ""; forYoudata += ""; count++; if (i === 7) { return false; } }); forYouApiResponse=forYoudata; $(forutxt).html('Recommended for you'); $(foruContent).html(forYoudata); } } }); } else if(forYouApiResponse!=''){ $(forutxt).html('Recommended for you'); $(foruContent).html(forYouApiResponse); } } function getUserData(){ $.ajax({ url:"https://www.hindustantimes.com/newsletter/get-active-subscription?usertoken="+user_token, type:"GET", dataType:"json", success: function(res){ if(res.length>0) { $("[id^=loggedin]").each(function(){ $(this).hide(); }); } } }); } function postUserData(payLoad, elm){ var msgelm=$(elm).parents(".subscribe-update").nextAll("#thankumsg"); $.ajax({ url:"https://www.hindustantimes.com/newsletter/subscribe", type:"POST", data:payLoad, contentType: "application/json", dataType: "json", success: function(res){ if(res.success===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); } else if(res.exceptionResponse.alreadySubscribed===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); $(msgelm).find(".subscribed-successfully:first span.msg").text(res.exceptionResponse.message); } } }); }function captchverification(captchaResponse) {$('#captchaResponse').value = captchaResponse;$("#captcha-div").removeClass("block");$("body").removeAttr("style");var payLoad=JSON.stringify({ "domain": "HT", "emailId": email, "googleCaptcha": captchaResponse, "subscriptionTypes": [ "daily" ] });postUserData(payLoad,activeElm);} function subscribeNewsletter(inputText) { activeElm=inputText; var mailformat = /^w+([.-]?w+)*@w+([.-]?w+)*(.w{2,3})+$/; if(inputText.val().match(mailformat)) { inputText.focus(); email=inputText.val(); $("#captcha-div").addClass("block"); $("body").css("overflow","hidden"); return true; } else { alert("You have entered an invalid email address!"); inputText.focus(); return false; } } //DFP Ads var $dfpRightAd1 = $('.dfp-rightAd1-' + storyUuid); var $dfpRightAd2 = $('.dfp-rightAd2-' + storyUuid); var $dfpRightAd3 = $('.dfp-rightAd3-' + storyUuid); var $dfpRightAd4 = $('.dfp-rightAd4-' + storyUuid); var $dfpRightAd5 = $('.dfp-rightAd5-' + storyUuid); var $dfpStoryAd1 = $('.dfp-storyAd1-' + storyUuid); var $dfpStoryAd2 = $('.dfp-storyAd2-' + storyUuid); var $dfpStoryAd3 = $('.dfp-storyAd3-' + storyUuid); var $dfpStoryAd4 = $('.dfp-storyAd4-' + storyUuid); var $dfpStoryAd5 = $('.dfp-storyAd5-' + storyUuid); var $centerAd = $('.centerAd-' + storyUuid); getPersonlizeData(''); displayAd($dfpRightAd1,'/1055314/HT_StoryPages_300x250_Top',[[300, 250], [300, 600]]); displayAd($dfpRightAd2,'/3106570/HT_Desk_Story_BS_Multisize',['fluid', [300, 100]]); var rightMiddleScrollHandler = function () { if ($dfpRightAd3.isInViewport()) { displayAd($dfpRightAd3, '/1055314/HT_StoryPages_300x250_Middle', [[300, 250], [300, 600]]); $(window).off("scroll", rightMiddleScrollHandler); } } $(window).on("scroll", rightMiddleScrollHandler); var rightTabRepTopScrollHandler = function () { if ($dfpRightAd4.isInViewport()) { displayAd($dfpRightAd4, '/1055314/HT_Desk_Story_TabRep_Top_Multisize', [[300, 250], [300, 600]]); $(window).off("scroll", rightTabRepTopScrollHandler); } } $(window).on("scroll", rightTabRepTopScrollHandler); var rightTabRepBottomScrollHandler = function () { if ($dfpRightAd5.isInViewport()) { displayAd($dfpRightAd5, '/1055314/HT_Desk_Story_TabRep_Bottom_Multisize', [300, 250]); $(window).off("scroll", rightTabRepBottomScrollHandler); } } $(window).on("scroll", rightTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAd.isInViewport()) { displayAd($centerAd, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Inline story ads var storyAd1ScrollHandler = function () { if ($dfpStoryAd1.isInViewport()) { displayAd($dfpStoryAd1, storyAdList[0].ad, [728, 90]); $(window).off("scroll", storyAd1ScrollHandler); } } $(window).on("scroll", storyAd1ScrollHandler); var storyAd2ScrollHandler = function () { if ($dfpStoryAd2.isInViewport()) { displayAd($dfpStoryAd2, storyAdList[1].ad, [728, 90]); $(window).off("scroll", storyAd2ScrollHandler); } } $(window).on("scroll", storyAd2ScrollHandler); var storyAd3ScrollHandler = function () { if ($dfpStoryAd3.isInViewport()) { displayAd($dfpStoryAd3, storyAdList[2].ad, [728, 90]); $(window).off("scroll", storyAd3ScrollHandler); } } $(window).on("scroll", storyAd3ScrollHandler); var storyAd4ScrollHandler = function () { if ($dfpStoryAd4.isInViewport()) { displayAd($dfpStoryAd4, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyAd4ScrollHandler); } } $(window).on("scroll", storyAd4ScrollHandler); var storyAd5ScrollHandler = function () { if ($dfpStoryAd5.isInViewport()) { displayAd($dfpStoryAd5, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyAd5ScrollHandler); } } $(window).on("scroll", storyAd5ScrollHandler); validateUser($("#loggedin"),$("#loggedout")); if(user_token){ $("#loggedin .subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata,this); }); }else{ $("#loggedout .subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); } function ScrollMe(uuid) {var id = uuid.replace('story_','').trim(); id = id +"_story";var newid = uuid.trim();$('#ulInfinite').each(function() {var phrase = '';$(this).find('li').each(function(j, lix) {var myid = $(lix).attr('id');if (myid.trim() == newid.trim())$(lix).addClass("active");else$(lix).removeClass("active");});});var element = document.getElementById(id);element.scrollIntoView();element.scrollIntoView({behavior : "auto",block : "start",inline : "nearest"});$('html, body').animate({scrollTop : $("#" + newid).offset().top - 800}, 800, 'swing');}function InfiniteScroll() {var nextURL = listUrl[urlCount];var $container = $('.articles').infiniteScroll({path : function() {return nextURL;},append : '.article',status : '.scroller-status',hideNav : '.pagination',loadOnScroll : false,scrollThreshold : false});$container.infiniteScroll('loadNextPage');$container.on('history.infiniteScroll', function(event, title, path) {var currentID = "article_" + getStoryIdByUrl('https://www.hindustantimes.com/india-news/tb-vaccine-averts-severe-infections-deaths-study/story-CERDmGhb0rWdjvUfCz8BKL.html');var articleID = "article_" + getStoryIdByUrl(path);document.title = title;var temp = path.replace('.html', '').split('-');temp = temp.reverse();var forNid = temp[0].trim();$('#ulInfinite li').removeClass("active");$('#story_' + forNid).addClass("active");var n = gatag.includes(articleID, 0);if(n==false){gatag.push(articleID);showSkippablePopup();ga('send', {hitType : 'pageview',location : window.location.hostname.trim(),title : title.trim(),page : window.location.pathname.trim(),dimension15 : title});}window.snowplow("trackPageView", title);window.snowplow('resetPagePing');if (typeof COMSCORE != 'undefined'&& typeof COMSCORE.beacon !== 'undefined') {COMSCORE.beacon({c1 : "2",c2 : "6035286"});}});$container.on('load.infiniteScroll', function(event, response, path) {urlCount++;});var counter = 1;var uuid;$container.on('append.infiniteScroll', function(event, response, path, items) {uuid= $(items).find('.get-uuid').val();var elmLogin=$(items).find('#loggedin');var elmLogout=$(items).find('#loggedout');getPersonlizeData(items); validateUser(elmLogin,elmLogout); if(user_token){ getUserData(); $(elmLogin).find(".subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $(items).find("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata, this); }); }else{ $(elmLogout).find(".subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $(items).find("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); }var $dfpRightAd1ES = $(items).find('.dfp-rightAd1-'+uuid); var $dfpRightAd3ES = $(items).find('.dfp-rightAd3-'+uuid); var $dfpRightAd4ES = $(items).find('.dfp-rightAd4-'+uuid); var $dfpRightAd5ES = $(items).find('.dfp-rightAd5-'+uuid); var $centerAdES = $(items).find('.centerAd-' + uuid); var $dfpStoryAd1ES = $('.dfp-storyAd1-' + uuid);var $dfpStoryAd2ES = $('.dfp-storyAd2-' + uuid); var $dfpStoryAd3ES = $('.dfp-storyAd3-' + uuid); var $dfpStoryAd4ES = $('.dfp-storyAd4-' + uuid); var $dfpStoryAd5ES = $('.dfp-storyAd5-' + uuid); var isVideoExists = $(items).find('.video-js'); var isVideo=false; if (isVideoExists.length > 0) { isVideo=true; } var rightESTopScrollHandler = function () { if ($dfpRightAd1ES.isInViewport()) { displayAd($dfpRightAd1ES, rightAdList[0].ad, rightAdList[0].adsizes); $(window).off("scroll", rightESTopScrollHandler); } } $(window).on("scroll", rightESTopScrollHandler); var rightESMiddleScrollHandler = function () { if ($dfpRightAd3ES.isInViewport()) { displayAd($dfpRightAd3ES, rightAdList[1].ad, rightAdList[1].adsizes); $(window).off("scroll", rightESMiddleScrollHandler); } } $(window).on("scroll", rightESMiddleScrollHandler); var rightESTabRepTopScrollHandler = function () { if ($dfpRightAd4ES.isInViewport()) { displayAd($dfpRightAd4ES, rightAdList[2].ad, rightAdList[2].adsizes); $(window).off("scroll", rightESTabRepTopScrollHandler); } } $(window).on("scroll", rightESTabRepTopScrollHandler); var rightESTabRepBottomScrollHandler = function () { if ($dfpRightAd5ES.isInViewport()) { displayAd($dfpRightAd5ES, rightAdList[3].ad, rightAdList[3].adsizes); $(window).off("scroll", rightESTabRepBottomScrollHandler); } } $(window).on("scroll", rightESTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAdES.isInViewport()) { displayAd($centerAdES, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Story Inline ads var storyESAd1ScrollHandler = function () { if ($dfpStoryAd1ES.isInViewport()) { displayAd($dfpStoryAd1ES, storyAdList[0].ad2, [728, 90]); $(window).off("scroll", storyESAd1ScrollHandler); } } $(window).on("scroll", storyESAd1ScrollHandler); var storyESAd2ScrollHandler = function () { if ($dfpStoryAd2ES.isInViewport()) { displayAd($dfpStoryAd2ES, storyAdList[1].ad2, [728, 90]); $(window).off("scroll", storyESAd2ScrollHandler); } } $(window).on("scroll", storyESAd2ScrollHandler); var storyESAd3ScrollHandler = function () { if ($dfpStoryAd3ES.isInViewport()) { displayAd($dfpStoryAd3ES, storyAdList[2].ad2, [728, 90]); $(window).off("scroll", storyESAd3ScrollHandler); } } $(window).on("scroll", storyESAd3ScrollHandler); var storyESAd4ScrollHandler = function () { if ($dfpStoryAd4ES.isInViewport()) { displayAd($dfpStoryAd4ES, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyESAd4ScrollHandler); } } $(window).on("scroll", storyESAd4ScrollHandler); var storyESAd5ScrollHandler = function () { if ($dfpStoryAd5ES.isInViewport()) { displayAd($dfpStoryAd5ES, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyESAd5ScrollHandler); } } $(window).on("scroll", storyESAd5ScrollHandler); counter++;if (urlCount = n && o = n ? t.play() : t.pause()) : console.log("iOS") }) }); }}else if(isVideo){$(items).find("video[id^='myPlayerID_']").each(function(t, e) {var n = "myPlayerID_" + $(e).attr("data-video-id");bc(n), videojs(n).ready(function() {this.scrollIntoView()}) });}$(items).find("div[id^='right-swiper-']").each(function(i, e) {var swipID = $(e).attr("id");var storySwiper = new Swiper('#' + swipID, {pagination : {el : '.swiper-pagination',clickable : true},preloadImages : false,lazyLoading : true,simulateTouch : false,autoplay : {delay : 3000,}});});var ind = 0;$(items).find('.read-more').each(function(ind, obj) {ind = ind + 1;var html = $(items).find("#inlineStory" + ind).html();$(this).html(html);});$(items).find('img.lazy').each(function(i, e) {$(e).lazyload({effect : "fadeIn",effectTime : 20,threshold : 200,failurelimit : 0});});//getSeoContent(items);});}var reqOpen = true;$(document).bind("scroll",function() {var viewport = {top : $(document).scrollTop(),left : $(document).scrollLeft()};viewport.bottom = viewport.top + $(document).height();lastScrollTop = viewport.top;var bot = viewport.bottom - $(document).height();if (viewport.top > 200 && (showInfinite)) {if(isCorona && !loaded){var s= document.createElement('script');s.setAttribute('async','');s.src="https://chat.amplify.ai/plugin/5e77327dd8722a5cf17170be/chat_plugin.js?pluginId=5e77327dd8722a5cf17170be";document.getElementsByTagName('head')[0].appendChild(s);loaded=true;}$('.footer-scroll-main').show();if (reqOpen == true) {$('#ulInfinite li:first').addClass("active");$('#ulInfinite li .stroy-link').each(function(i, t) {if(i>0){listUrl.push($(t).html());}});InfiniteScroll();reqOpen = false;} } else if (bot

View post:

TB vaccine averts severe infections, deaths from Covid-19: Study - Hindustan Times

(UroToday.com)As part of a plenary presentation at the European Association of Urology (EAU)Virtual Annual Meeting assessing Modern prostate cancer imaging in daily practice, Dr. Jenster examined the role of genomics to complement imaging in patients undergoing investigation for prostate cancer.

As with any approach in medicine, there are limits to the use of imaging in prostate cancer diagnosis. Beyond issues related to the human interaction with these modalities, imaging limitations relate to both technical and non-technical factors and include the detection limits of imaging modalities, the specificity for cancerous vs non-cancerous prostate tissue, false-negative results, false-positive results, heterogeneity both within and between tumors, and molecular tumor characteristics. Genomic testing offers the ability to address many of these issues.

Dr. Jenster considered the role of imaging approaches, histopathology, and genomics across a range of clinical scenarios in the natural history of prostate cancer rather than pre-diagnostic risk stratification to the monitoring of response and progression. As highlighted in the table below, various approaches have particular strengths and weaknesses so a synergistic use may provide the most appropriate information for guiding treatment decision making at any given step in the disease process.

Highlighting data from Salmasi et al., there is concordance in the GenomeDx Genomic Prostate Score (GPS) and MRI based PiRADS score suggesting that genomic changes and radiographic changes correlate.

For pre-diagnostic risk stratification, Dr. Jenster stressed the importance of testing using biofluids including urine and blood. Based on the specific assay in question, a variety of approaches may be employed including proteins, cell-free RNA, circulating tumor cells (CTCs), cell-free DNA, metabolites, extracellular vesicles, platelets, viruses, and other micro-organisms.

A number of commercially available assays have utilized urine DNA methylation for risk stratification. While each assesses different gene loci, the underlying principle is the same.

While not commercially available, assessment of extracellular micro-vesicles allows assessment of many biomarkers including miRNAs, snoRNAs, and tRNAs. However, plasma cell free DNA offers the potential to sequence underlying genetic changes to allow for targeted treatment.

Genomic testing may also allow the identification of novel imaging targets, such as novel prostate cancer-specific membrane proteins. A number of these are under investigation, leading to clinical trials.

Dr. Jenster concluded highlighting the complementary nature of imaging and genomic testing to resolve within and between tumor heterogeneity, complete diagnosis and prognosis, inform personalized treatment choice and guide further investigations.

Presented by: Guido Jenster, PhD,Associate Professor of Urology, Erasmus MC

Written by: Christopher J.D. Wallis, Urologic Oncology Fellow, Vanderbilt University Medical CenterContact: @WallisCJD on Twitterat the Virtual 2020 EAU Annual Meeting #EAU20, July 17-19, 2020

See more here:

EAU 2020: What Might Genomics Add to the Decision? - UroToday